Bristol Myers on Why Neuroscience Could Be the Next Oncology

“Neuroscience is what oncology was 20 years ago,” says Cristian Massacesi, Chief Medical Officer and Head of Development at Bristol Myers Squibb. Massacesi joins Bloomberg Intelligence pharmaceuticals analyst Sam Fazeli to discuss Bristol Myers’ push into neuroscience, including Alzheimer’s therapies aimed at tau, a protein tied to brain tangles in the disease. They also explore the company’s oncology pipeline, including PD-L1/VEGF bispecifics, next-generation antibody-drug conjugates and advances in multiple myeloma. Massacesi explains how Bristol is balancing internal innovation with external partnerships and why AI could fundamentally change the economics and success rates of drug development.See omnystudio.com/listener for privacy information.